Business
Harbour BioMed Announces Positive Profit Alert for 2025 Annual Results
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a positive profit alert for the year ended December 31, 2025.
About this update from Hbm Holdings Ltd.
[{"type":"text","content":"CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 3, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a positive profit alert for the year ended December 31, 2025.","length":356,"tagName":"p"},{"type":"image","alt":"Logo (PRNewsfoto/Harbour BioMed)","displaySize":"","headline":null,"caption":"Logo (PRNewsfoto/Harbour BioMed)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":159,"url":"https://media.zenfs.com/en/prnewswire.com/47f569ac406a18e992467aae42c1112a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QANxnzzeBFHKxcqoWHourA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI4MDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/47f569ac406a18e992467aae42c1112a","width":400,"height":159}},"href":"https://mma.prnewswire.com/media/1096360/HB_for_email_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Based on a preliminary review of the Company's unaudited management accounts for the Reporting Period, total profit is expected to range between US$88 million (equivalent to approximately HK$685 million) and US$95 million (equivalent to approximately HK$739 million), as compared to a profit of approximately US$2.7 million for the year ended December 31, 2024. Total adjusted profit[1] is expected to range between US$91 million (equivalent to approximately HK$708 million) and US$98 million (equivalent to approximately HK$763 million).","length":542,"tagName":"p"},{"type":"text","content":"The anticipated increase in profit is primarily attributable to:","length":64,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Continued growth of recurring revenue stream of the Company, such as the platform-based research collaboration with AstraZeneca and Bristol Myers Squibb.","length":158,"tagName":"p"}]},{"val":[{"type":"text","content":"Accelerated expansion of global partner network, as the revenue generated from out-licensing and collaboration of innovative products has transformed into recurring revenue stream of the Company, such as the licensing collaboration with Otsuka, the licensing collaboration with Windward Bio.","length":296,"tagName":"p"}]},{"val":[{"...